Regeneron announced that it will spend $1.8 billion to expand its Tarrytown, N.Y., campus over a six-year period, creating 1,000 new jobs.

The updated Regeneron site will include new preclinical manufacturing and process development suites, laboratories and a central plant totaling an estimated 900,000 square feet.

Regeneron, which received an Emergency Use Authorization from the FDA in November 2020 for its COVID-19 antibody cocktail, REGEN-COV, is also developing medicines for a wide range of other diseases and conditions.